Despite many advances, our understanding of the involvement of prodynorphin systems in the development of neuropathic pain is not fully understood. Recent studies suggest an important role of neuroeglial interactions in the dynorphin effects associated with neuropathic pain conditions. Our studies show that minocycline reduced prodynorphin mRNA levels that were previously elevated in the spinal and/or dorsal root ganglia (DRG) following sciatic nerve injury. The repeated intrathecal administration of minocycline enhanced the analgesic effects of low-dose dynorphin (0.15 nmol) and U50,488H (25e100 nmol) and prevented the development of flaccid paralysis following high-dose dynorphin administration (15 nmol), suggesting a neuroprotective effect. Minocycline reverts the expression of IL1b and IL-6 mRNA within the spinal cord and IL-1b mRNA in DRG, which was elevated following intrathecal administration of dynorphin (15 nmol). These results suggest an important role of these proinflammatory cytokines in the development of the neurotoxic effects of dynorphin. Similar to minocycline, a selective inhibitor of MMP-9 (MMP-9 levels are reduced by minocycline) exerts an analgesic effect in behavioral studies, and its administration prevents the occurrence of flaccid paralysis caused by high-dose dynorphin administration (15 nmol). In conclusion, our results underline the importance of neuroeglial interactions as evidenced by the involvement of IL-1b and IL-6 and the minocycline effect in dynorphin-induced toxicity, which suggests that drugs that alter the prodynorphin system could be used to better control neuropathic pain.
Introduction
Endogenous opioid systems are one of the most important systems that control nociception. Opioids have been used for the treatment of pain due to their analgesic effects (Przewlocki and Przewlocka, 2005) . The role of dynorphin in the development of chronic pain is particularly interesting, but it has not been fully elucidated. Numerous studies note the non-opioid effects of dynorphin in neuropathic pain (Draisci et al., 1991; Laughlin et al., 1997; Obara et al., 2003; Mika et al., 2011) . Prodynorphin level in the lumbar spinal region increases following peripheral nerve injury, as demonstrated for the first time in Northern blot assays (Faden et al., 1985; Przewłocki et al., 1988) and later using in situ hybridization (Obara et al., 2003) . Dynorphin exerts analgesic effects via the KOP receptor (Walker et al., 1982; Przewłocki et al., 1983; Vanderah et al., 1996; Laughlin et al., 1997; Jolivalt et al., 2006) . However, the intrathecal administration of dynorphin at high doses enhances the release of stimulatory neurotransmitters and cytokine synthesis and induces flaccid paralysis (Faden, 1990; Dubner and Ruda, 1992) . These effects are not inhibited following the administration of an opioid receptor antagonist, naloxone, but they are reduced following the earlier administration of an NMDA receptor antagonist, MK-801 (Vanderah et al., 1996; Laughlin et al., 1997) . The effects of dynorphin are bimodal; the administration of high doses of dynorphin enhances intracellular levels of Ca 2þ via the simultaneous activation of NMDA and KOP receptors, but the administration of low doses activates only KOP receptors (Laughlin et al., 1997; Hu et al., 1998) . Whether microglia, which are strongly activated during the development of neuropathic pain, impact the effects of dynorphin is unknown. Dynorphin is synthesized by neurons (Sasek et al., 1984) , oligodendrocytes (Knapp et al., 2001) but not by astrocytes (Shinoda et al., 1989) . Machelska (2007) revealed that various immune cells, including lymphocytes and macrophages, may produce dynorphin, which plays an important role in the regulation of cellular and humoral immune responses and affects cytokine production. During neuropathy, neurons and glia exchange signals through cytokines (Mika et al., 2008; Austin and Moalem-Taylor, 2010) . The activation of p38MAPK triggers the production of pronociceptive and antinociceptive cytokines, which play an important role in nociception (DeLeo and Yezierski, 2001; Mika et al., 2008 Mika et al., , 2013 ) . Neuropathic pain develops due to a disturbance in the equilibrium between algesic and analgesic cytokines, therefore, for our study we chose two pronociceptive (IL1beta, IL-6) and two antinociceptive (IL-1alpha, IL-10) cytokines. Minocycline which is a tetracycline derivative with pleiotropic biological effects inhibits spinal p38MAPK activation in microglia (Hains and Waxman, 2006) , decreases proinflammatory cytokine levels and attenuates neuropathic pain development after nerve injury. Some authors show that minocycline can influence neurons in cultures (Gieseler et al., 2009; Mishra et al., 2009) , others that reduces pain via the inhibition of Ca 2þ and Na þ currents in sensory neurons (Kim et al., 2011; Liu et al., 2013) . It was also documented that minocycline inhibited MMP-9 activity, which is one of the targets of this drug. In 2008, Kawasaki et al. demonstrated the crucial role of MMP-9 in the development of neuropathic pain. Moreover, MMP-9 is one of the targets of minocycline. It was interesting to check whether blocking of MMP-9 will trigger the same effect on the toxic dynorphin action as that caused by minocycline. Our previously published studies suggest that intraperitoneal minocycline treatment parallels the inhibition of C1q-positive cells (microglia, monocytes and polymorphonuclear leukocytes) and decreases the nerve injury-induced increase of the prodynorphin mRNA level (Mika et al., 2010 ). An understanding of the molecular mechanisms of the prodynorphin system in neuropathic pain, with particular focus on the interactions between microglia and neurons, should improve the possibility of reducing the toxic effects of dynorphin in neuropathic pain. Therefore, the goal of our study was to pharmacologically modulate the prodynorphin system in neuropathic pain. First, the aim of our studies was to determine the role of microglia in the effects of dynorphin using minocycline, an inhibitor of microglial activation. We examined the effects of repeated intrathecal minocycline administration on the effects of U50,488H, dynorphin and norBNI, k-opioid (KOP) receptor ligands, during neuropathic pain.
Second, we used qRT-PCR to determine changes in the biosynthesis of C1q, MMP-9, PDYN and interleukins (antinociceptive IL-1a, IL-10; pronociceptive IL-1b, IL-6) under neuropathic pain and/or following intrathecal dynorphin administration. Third, we performed repeated intrathecal administrations of MMP-9 inhibitor I and examined the influence of this inhibitor on dynorphin-induced toxicity during neuropathic pain.
Materials and methods

Animals
Male Wistar rats (300e350 g) from Charles River (Hamburg, Germany) were housed in cages lined with sawdust under a standard 12/12 h light/dark cycle (lights on at 08:00 h) with food and water ad libitum. All efforts were made to minimize animal suffering and to reduce the number of animals used. All experiments were performed according to the recommendations of the International Association for the Study of Pain (IASP) (Zimmermann, 1983) and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The local Bioethics Committee approved all experiments (Krakow, Poland).
Intrathecal catheter implantation
The rats were chronically implanted with intrathecal (i.t.) catheters according to the methods of Yaksh and Rudy (1976) under pentobarbital anesthesia (60 mg/kg; i.p.). The catheter (PE 10, INTRAMEDIC, Clay Adams, Becton Dickinson and Company, Rutherford, NJ, USA) was rinsed via immersion in 70% ethanol and fully flushed with sterile water prior to insertion. The catheter was carefully introduced through the atlanto-occipital membrane and advanced to the subarachnoid space at the rostral level of the spinal cord lumbar enlargement (L4eL6).
Chronic constriction injury
Chronic constriction injury (CCI) was produced according to the methods of Bennett and Xie (1988) . The right sciatic nerve was exposed under sodium pentobarbital anesthesia (60 mg/kg; i.p.). Four ligatures (4/0 silk) were made around the nerve distal to the sciatic notch with 1-mm spacing until a brief twitch in the respective hind limb was observed. All rats after surgery developed long-lasting neuropathic pain symptoms, such as allodynia and hyperalgesia. CCI of the sciatic nerve was performed five days after catheter implantation.
Drug administration
Minocycline hydrochloride (MC; 60 mg/5 ml; Sigma, Schnelldorf, Germany) was dissolved in water for injections and administered preemptively via i.t. injection 16 and 1 h before CCI and then once daily for 7 days as described previously . This administration schedule was used because systemic microglia inhibitors attenuate the activation of microglia more efficiently when the inhibitor is injected before injury (Raghavendra et al., 2003; Ledeboer et al., 2005) . The control groups received vehicle (water for injection) according to the same schedule (Scheme 1). All drugs were injected i.t. at a volume of 5 ml, followed by an injection of 10 ml of bidistilled water to flush the catheter. Dynorphin A (1e17) (DYN; 0.15 and 15 nmol/5 ml; Tocris, Warsaw, Poland) was dissolved in water for injections and administered via i.t. injection 7 days after CCI (Laughlin et al., 2000; Wang et al., 2009 ). U50,488 hydrochloride (U50,488H; 25 and 100 nmol/5 ml; U50; Tocris, Warsaw, Poland) was dissolved in water for injections and administered via i.t. injection 7 days after CCI (Omana et al., 1994) . MMP-9 inhibitor I (MMP-9 INH.I, 5 mg/5 ml, Merc Millipore, Warsaw, Poland) was dissolved in 50% DMSO and administered preemptively via i.t. injection 16 and 1 h before CCI and then once daily for 7 days or as a single injection 7 days after CCI (Kawasaki et al., 2008) . norBinaltorphimine dihydrochloride (norBNI; 6.8 and 13.6 nmol/5 ml; Tocris, Warsaw, Poland) was dissolved in water for injections and administered via i.t. injection 7 days after CCI. The control groups received vehicle (water for injections or DMSO) according to the same schedule.
Behavioral tests
Tactile allodynia (von Frey test)
Allodynia was measured using electronic von Frey apparatus (Dynamic Plantar Anesthesiometer Cat. No. 37400, Ugo Basile, Italy). Animals were placed in plastic cages with wire net floors 5 min before the experiment. The von Frey filament was applied to the midplantar surface of the hind paw, and measurements were taken automatically as described previously (Mika et al., , 2010 Makuch et al., 2013) . We tested the ipsilateral paw two times in 3-min intervals, and the mean value was calculated. The strengths of the von Frey stimuli used in our experiments were up to 26 g. There was almost no response in naïve animals to the highest strengths.
Thermal hyperalgesia (cold plate test)
Hyperalgesia was assessed using the cold plate test (Cold/Hot Plate Analgesia Meter No. 05044, Columbus Instruments, USA) as described previously (Mika et al., , 2010 Makuch et al., 2013) . The temperature of the cold plate was maintained at 5 C, and the cut-off latency was 30 s. The animals were placed on the cold plate, and the time until a lifting of the hind paw occurred was recorded. The reaction of the first hind paw to be lifted in the naïve rat group was measured. The injured paw was the first to react in all cases.
Biochemical tests 2.6.1. Tissue collection and RNA isolation
Ipsilateral fragments of the dorsal part of the lumbar (L4eL6) spinal cord and the DRG (L4eL6) were removed immediately after decapitation on day 7 following CCI, 4 h after MC administration. The tissue samples were placed in individual tubes with the RNAlater tissue storage reagent (Qiagen Inc., Valencia, USA) and stored at À70 C for RNA isolation. Total RNA was extracted using TRIzol reagent (Invitrogen) as described previously (Chomczynski and Sacchi, 1987) . The RNA concentration was measured using a NanoDrop ND-1000 Spectrometer (ND-1000, NanoDrop Technologies, Montchanin, DE), and RNA quality was determined using chip-based capillary electrophoresis with an RNA 6000 Nano LabChip Kit and Agilent Bioanalyzer 2100 (Agilent) according to the manufacturer's instructions.
Quantitative PCR
Reverse transcription was performed on 2 mg of total RNA using Omniscript reverse transcriptase (Qiagen Inc.) at 37 C for 60 min. RT reactions were performed in the presence of an RNAse inhibitor (rRNAsin, Promega) and oligo (dT16) primer (Qiagen Inc.). cDNA was diluted 1:10 with H 2 O, and~50 ng of cDNA synthesized from the total RNA template from individual animals was used for each quantitative RealTime PCR (RT-qPCR) reaction. RT-qPCR was performed using Assay-On-Demand TaqMan probes according to the manufacturer's protocol (Applied Biosystems) and run in an iCycler device (BioRad, Hercules). A standard dilution curve determined the amplification efficiency for each assay. The following TaqMan primers and probes were used: Rn01527838_g1 (HPRT, hypoxanthine guanine rat hypoxanthine guanine phosphoribosyl transferase); Rn00570480_m1 (C1q, complement component 1q); Rn00579162_m1 (MMP-9, metalloproteinase 9); Rn00571351_m1 (PDYN, prodynorphin); Rn00566700_m1 (IL-1a, interleukin 1alpha); Rn00563409_m1 (IL-10, interleukin 10); Rn00580432_m1 (IL-1b, interleukin 1beta) and Rn00561420_m1 (IL-6, interleukin 6). A standard dilution curve determined the amplification efficiency for each assay (between 1.7 and 2). The cycle threshold values were calculated automatically by iCycler IQ 3.0 software using the default parameters. RNA abundance was calculated as 2 -(threshold cycle) . HPRT transcript levels do not significantly change in rats exposed to CCI (Mika et al., 2010) , and therefore, this transcript served as an adequate housekeeping gene.
Data analysis
All graphs and analyses were prepared using GraphPad Prism (version 5.0). The behavioral data are presented in grams and seconds as means ± SEM, and each Scheme 1. Drug administration.
Scheme 2. Dynorphin may play a physiological role and exert antinociceptive effects via the opioid receptor and induce pathological and pronociceptive effects via non-opioid mechanism e.g. activation of the NMDA receptor (A). Minocycline decreased the activation of microglia and the levels of MMP-9, IL-1b and IL-6 mRNA after nerve injury and dynorphin-induced IL-1b and IL-6 mRNA (B). Our research enriches and systematizes our knowledge of the actions of dynorphin and adds new facts to our knowledge of the opioid and non-opioid action of this peptide. Dynorphin may play a physiological role via the opioid receptor (Przewłocki et al., 1983; Stevens and Yaksh, 1986) , and it has antinociceptive effects. Dynorphin also induces pathological effects via activation of the NMDA receptor to produce pronociceptive effects (Vanderah et al., 1996; Laughlin et al., 1997; Obara et al., 2003) (Scheme 2a). The administration of KOP receptor antagonists norbinaltorphimine (norBNI) and 5 0 -guanidinonaltrindole (GNTI) enhanced allodynia after sciatic nerve ligation (Obara et al., 2003) . The potentiation of allodynia after norBNI or GNTI administration was inhibited by the earlier administration of ketamine, an NMDA receptor antagonist (Obara et al., 2003) . The present studies suggest that neurons and microglia are involved in these effects (Scheme 2b). KOP and NMDA receptors induce p38MAPK activation (Lemos et al., 2012) . High doses of DYN induce the activation of NMDARs (Obara et al., 2003) , causing the activation of p38MAPK. These results suggest that these mechanisms induce the synthesis of pronociceptive cytokines, such as IL-1b and IL-6. Duarte et al. (2012) suggest that the regulation of MMP-9 is via the p38MAPK pathway, which can also be the mechanism of minocycline. MMP-9 induces neuropathic pain through IL-1b cleavage and microglial activation (Scheme 2a). Notably, minocycline administration prevented flaccid paralysis. We have shown that minocycline decreased the activation of microglia and the levels of MMP-9, IL-1b and IL-6 mRNA after nerve injury and DYN-induced increase in IL-1b and IL-6 mRNA levels (Scheme 2b). group consisted of 6e15 rats. The results of the experiments were evaluated using one-way analysis of variance (ANOVA). ***p < 0.001 indicates a significant difference marked only between control (naïve rats) and vehicle-treated CCI-exposed rats; # p < 0.05, ## p < 0.01 and ### p < 0.001 indicate a significant difference vs. vehicletreated CCI-exposed rats; & p < 0.05 and &&& p < 0.001 indicate a significant difference vs. minocycline and MMP-9 inhibitor I-treated CCI-exposed rats; and^p < 0.05 and^^^p < 0.001 indicate a significant difference vs. KOP-receptor ligand-treated CCIexposed rats.
The results of qRT-PCR are presented as fold changes compared to controls (naive rats), and the results were calculated for the ipsilateral sides of the spinal cords and DRG of CCI-exposed rats. The quantitative qPCR analysis data are presented as means ± SEM, which represent normalized averages derived from the threshold cycle in qPCR from 8 to 10 samples for each group. Inter-group differences were analyzed using an ANOVA, followed by Bonferroni's repeated comparison test. *p < 0.05 and ***p < 0.001 indicates a significant difference marked only between control (naïve rats) and vehicle-treated CCI-exposed rats; # p < 0.05, ## p < 0.01 and ### p < 0.001 indicate a significant difference vs. vehicle-treated CCI-exposed rats; && p < 0.01 and &&& p < 0.001 indicate a significant difference vs. minocycline-treated CCI-exposed rats; and^p < 0.05 and^^^p < 0.001 indicate a significant difference vs. dynorphin A (1e17) -treated CCI-exposed rats.
Results
3.1. Effects of minocycline and dynorphin A (1e17) administration on C1q, MMP-9 and PDYN mRNA levels in the spinal cord and DRG of rats 7 days after CCI
The expression of complement component 1, q subcomponent (C1q), metalloproteinase 9 (MMP-9) and prodynorphin (PDYN) mRNA in the spinal cord and DRG was determined using qRT-PCR. A 720% increase in the mRNA of C1q was observed in the spinal cord after CCI, and a 440% increase was observed in the DRG. Minocycline (60 mg/5 ml, i.t.) significantly diminished the injury-induced increase in C1q mRNA levels in the spinal cord and DRG. No effects of a single administration of DYN (15 nmol) on the elevated C1q mRNA level following CCI were observed in either structure. A single dose of DYN (15 nmol) administered to MC-treated rats did not influence C1q mRNA level as compared to vehicle-treated CCIexposed rats in the spinal cord or DRG (Table 1) .
A 430% strong upregulation of the MMP-9 mRNA level was detected in the spinal cord after CCI, and a 50% increase was observed in the DRG. Minocycline significantly diminished the injury-induced increase in the MMP-9 mRNA level in the spinal cord from 430% to 50%). Minocycline did not alter MMP-9 mRNA levels in the DRG (Table 1) .
A single administration of DYN (15 nmol) had no effect on the injury-induced changes in MMP-9 mRNA expression in either of the tested structures. In animals receiving repeated doses of minocycline, the increase in MMP-9 mRNA expression in the spinal cord following DYN administration was lower than that following administration of DYN alone. However, no changes were demonstrated in the DRG (Table 1) .
A strong increase in PDYN mRNA, amounting to 2680%, was observed in the spinal cord following sciatic nerve ligation, and a 1380% increase was observed in the DRG. Intrathecal minocycline significantly diminished the injury-induced increase in PDYN mRNA from 2680% to 850% in the spinal cord, but no significant effect of minocycline was observed in the DRG (Table 1) .
We have shown that minocycline inhibits the activation of microglia and MMP-9, and significantly inhibits injury-induced increase in PDYN expression, therefore, in the next experiment we checked whether the nociceptive effect of kappa receptor ligands is altered by minocycline treatment of CCI-exposed rats.
3.2. Effect of repeated minocycline administration on the effects of norBNI, U50,488 and dynorphin A (1e17) after administration in rats 7 days after CCI All CCI-exposed rats developed neuropathic pain symptoms, such as allodynia or hyperalgesia. The strong allodynia and hyperalgesia was already observed on the third day after CCI (data not shown). The reaction to the mechanical stimulus (von Frey test) in control rats was observed at 26.0 g ± 0.7, and the reaction to low temperature was observed after 27.3 s ± 2.4 (cold plate test). Reductions in pain thresholds after CCI were observed in the von Frey test and the cold plate test and minocycline (MC, 60 mg/5 ml, i.t.) diminished the allodynia (Fig. 1A, C , E, G, I, K) and hyperalgesia (Fig. 1B, D, F, H, J, L) . norBNI was i.t. administered at two doses: 6.8 nmol and 13.6 nmol 30 min after the last injection of minocycline. The lower dose (6.8 nmol) had no effect on allodynia (14.3 g ± 0.6 vs. 13.6 g ± 0.5; Fig. 1A ) but enhanced hyperalgesia (8.0 s ± 0.7 vs. 4.9 s ± 0.8; Fig. 1B) . The high doses of norBNI (13.6 nmol) enhanced both allodynia (14.3 g ± 0.6 vs. 11.3 g ± 0.6; Fig. 1C ) and hyperalgesia (8.0 s ± 0.7 vs. 5.0 s ± 0.6; Fig. 1D ). The analgesic effect of minocycline remained unchanged following low and high doses of norBNI. U50,488H was i.t. administered at two doses: 25 nmol and 100 nmol 30 min after last injection of minocycline. The lower dose (25 nmol) had an analgesic effect in the von Frey test (12.5 g ± 0.4 Table 1 The effect of repeated intrathecal minocycline administration (MC, 60 mg/5 ml, 16 and 1 h before sciatic nerve injury and then once daily for 7 days) and dynorphin A (1e17) (DYN) on the changes in the expression of the mRNA of C1q, metalloproteinase-9 (MMP-9) and prodynorphin (PDYN) on day 7 following sciatic nerve ligation (CCI) as measured in the spinal cord and DRG. The values were standardized against HPRT. The results are presented as fold changes of control (Naïve). Inter-group differences were analyzed by ANOVA Bonferroni's Multiple Comparison Test: *p < 0.05, ***p < 0.001 Naive vs. V þ V CCI-exposed rats; # p < 0.05, ### p < 0.001 vs. V þ V CCI-exposed; && p < 0.01 differences between MC þ V and MC þ DYN CCI-exposed rats;^p < 0.05,^^^p < 0.001 differences between V þ DYN and MC þ DYN CCI-exposed rats. Vehicle (V; water for injection).
vs. 14.8 g ± 0.5; Fig. 1E ), but no effect was observed in the cold plate test (7.3 s ± 0.7 vs. 10.0 s ± 1.8; Fig. 1F ). The analgesic effect of minocycline remained unchanged following low dose U50,488H administration, as demonstrated in von Frey's test (17.8 g ± 0.7 vs. 17.7 g ± 0.7; Fig. 1E ) and the cold plate test (12.7 s ± 1.8 vs. 12.5 s ± 3.0; Fig. 1F ). The high dose (100 nmol) had an analgesic effect in the von Frey (12.5 g ± 0.4 vs. 14.9 g ± 0.4; Fig. 1G ), cold plate test (7.3 s ± 0.7 vs. 13.4 s ± 2.8; Fig. 1H ). The administration of higher doses of U50,488H to animals previously receiving minocycline enhanced the analgesic effect in von Frey's test (Fig. 1G) but not in the cold plate test (Fig. 1H) . DYN was i.t. administered at two doses: 0.15 nmol and 15 nmol. Analgesic effects were demonstrated 30 min following the administration of the lower dose of DYN (0.15 nmol) in the von Frey (11.0 g ± 0.4 vs. 19.3g ± 0.8; Fig. 1I ) and cold plate (6.3 s ± 0.5 vs. 17.4 s ± 1.0) tests (Fig. 1J) . Additionally, the DYN antinociceptive effect, but not paralysis, was blocked by norBNI (13.6 nmol) administration (Table 2) . Additionally, the DYN antinociceptive effect, but not paralysis, was blocked by norBNI (13.6 nmol) administration (Table 2 ). In animals previously receiving minocycline, we observed enhanced analgesic effects of low-dose DYN(1-17) (0.15 nmol) on hyperalgesia (Fig. 1J ). High doses of DYN (15 nmol) caused flaccid paralysis, which made measurement of hypersensitivity to mechanical (Fig. 1K ) and thermal stimuli (Fig. 1L) impossible. Minocycline prevented the occurrence of flaccid paralysis following high dose DYN administration (Fig. 1K, L) .
The results indicate that administration of 15 nmol of DYN causes neurotoxic effects resulting in flaccid paralysis. Blocking these neurotoxic effects by minocycline suggests an involvement of nociceptive factors and, therefore, in next experiments we checked the changes in the well known pro-and antinociceptive interleukins.
3.3. Effect of minocycline and dynorphin A (1e17) administration on mRNA levels of antinociceptive IL-1a and IL-10 in the spinal cord and DRG in rats 7 days after CCI The qRT-PCR method revealed no changes in the expression of anti-inflammatory IL-1a and IL-10 mRNA in the spinal cord following CCI ( Fig. 2A, C) . In contrast, a 4100% upregulation of IL-1a mRNA was observed in the DRG (1.0 ± 0.05 vs. 42.0 ± 5.1; Fig. 2B ), while IL-10 mRNA expression increased by 400% (1.0 ± 0.1 vs. 5.0 ± 1.8; Fig. 2D ).
No significant effects on IL-1a and IL-10 mRNA levels in either tested structure were observed after minocycline administration or following a single DYN administration (15 nmol/5 ml; Fig. 2A , B, C, D). Additionally, DYN administration previously receiving repeated doses of minocycline had no effect on the changes in IL-1a ( Fig. 2A,  B) and IL-10 mRNA (Fig. 2C, D ) levels in the spinal cord and in DRG. Our results indicate that after minocycline administration, a single DYN dose does not influence the level of this antinociceptive interleukin under neuropathic pain.
3.4. Effect of minocycline and dynorphin A (1e17) administration on the mRNA levels of pronociceptive interleukins IL-1b and IL-6 in the spinal cord and DRG in rats 7 days after CCI
The upregulation of IL-1b mRNA, amounting to 310%, was observed in the spinal cord (1.0 ± 0.2 vs. 4.1 ± 0.2; Fig. 2E) , and a 130% increase of IL-1b mRNA was detected in the DRG (1.0 ± 0.2 vs. 2.3 ± 0.6; Fig. 2F ) following CCI. A strong upregulation of 710% for IL-6 mRNA was observed in the spinal cord (1.0 ± 0.1 vs. 8.1 ± 2.0; Fig. 2G ), together with a very strong (8900%) increase in the DRG (1.0 ± 0.3 vs. 90.1 ± 6.5; Fig. 2H ). Minocycline significantly diminished the injury-induced increase in IL-1b mRNA in the spinal cord (4.1 ± 0.2 vs. 2.6 ± 0.3; Fig. 2E ) but not in the DRG (2.3 ± 0.6 vs. 1.7 ± 0.6; Fig. 2F ). The expression of IL-6 mRNA in the spinal cord in animals receiving minocycline was lower compared to animals following nerve injury (8.1 ± 2.0 vs. 3.7 ± 1.9; Fig. 2G ). The expression of IL-6 mRNA in the DRG was lower (4700% instead of 8900%) after minocycline administration (90.1 ± 6.5 vs. 47.6 ± 4.6; Fig. 2H ).
A single administration of DYN (15 nmol/5 ml) resulted in a strong (1730%) upregulation of IL-1b mRNA (4.1 ± 0.2 vs. 18.3 ± 3.0) in the spinal cord (Fig. 2E) and a 630% increase in the DRG (2.3 ± 0.6 vs. 7.3 ± 2.0; Fig. 2F) . A strong increase of 4560% in the expression of IL-6 mRNA was also observed within the spinal cord following DYN administration (8.1 ± 2.0 vs. 46.6 ± 15.1; Fig. 2G ), but no effect of DYN on IL-6 mRNA levels was observed in the DRG (Fig. 2H) . In animals previously receiving repeated doses of minocycline, DYN administration was associated with a lower change in spinal IL-1b mRNA expression than DYN administration alone, from 1730% to 490% (18.3 ± 3.0 vs. 5.9 ± 1.1; Fig. 2E ) and from 630% to 260% in the DRG (7.3 ± 2.0 vs. 3.6 ± 0.6; Fig. 2F ). In addition, downregulation of mRNA IL-6 from 4560% to 260% was demonstrated in the spinal cord (46.6 ± 15.1 vs. 3.6 ± 1.4; Fig. 2G ), but no effects on the expression within the DRG were observed (Fig. 2H) .
Our results indicate that minocycline influences the level of the examined pronociceptive interleukins under neuropathic pain, and that IL-1beta and IL-6 seems to play an important role in DYNinduced neurotoxicity.
Effect of repeated metalloproteinase-9 inhibitor (MMP-9 INH.I) administration on the effect of dynorphin A (1e17) in rats 7 days after CCI
We observed that minocycline diminished the level of MMP-9 in DYN-treated CCI-exposed rats (Table 1) , therefore, we studied whether the inhibition of MMP-9 will also reverse the neurotoxic effects of high doses of DYN in the same experimental scheme. The control group consisted of animals without sciatic nerve injury. The reaction to mechanical stimuli (von Frey's test) was observed at 26.0 ± 0.7 g, and the reaction to low temperature was observed after 27.3 ± 2.4 s (cold plate test). Reductions in the pain threshold in animals with sciatic nerve ligation were observed in the von Frey test (12.5 g ± 0.4; Fig. 3A ) and the cold plate test (7.3 s ± 0.7; Fig. 3B ). DYN (DYN, 15 nmol) caused flaccid paralysis. The effect of DYN was observed 30 min after DYN administration, and persisted for up to 24 h after administration (data not shown).
Repeated administrations of MMP-9 INH.I reduced allodynia (11.0 g ± 0.4 vs. 15.1 g ± 2.2; Fig. 3A ) and hyperalgesia (5.8 s ± 0.4 vs. 14.0 s ± 2.1; Fig. 3B ). An analgesic effect of MMP-9 INH.I was also demonstrated after 24 h in the von Frey test (20.0 g ± 1.5) and the cold plate test (15.1 s ± 1.7; data not shown).
Our results indicate that similarly to minocycline, a selective inhibitor of MMP-9 exerts an analgesic effect in behavioral studies, and its administration prevents the occurrence of flaccid paralysis caused by dynorphin administration.
Discussion
Numerous studies confirm that nerve injury increases prodynorphin mRNA, which correlates with the onset of neuropathic pain symptoms (Kajander et al., 1990; Draisci et al., 1991; Malan et al., 2000; Wang et al., 2001; Obara et al., 2003; Mika et al., 2011) . Studies of prodynorphin gene knock-out mice show that animals normally respond to nociceptive stimuli, which suggests that the role of dynorphin in nociception is primarily related to pathological processes. A single intrathecal administration of dynorphin causes long-lasting allodynia (Vanderah et al., 1996; Laughlin et al., 1997) , particularly at high doses. Typical painrelated behaviors, such as gnawing or licking, were described following the intrathecal administration of a high doses of DYN (Tan-No et al., 2002) . High doses of DYN (15e50 nmol) in rats were also used as a model of neuropathic pain because they cause neurotoxic effects and damage sensory neurons, motoneurons and interneurons in the gray matter of the spinal cord (Herman et al., 1980; Long et al., 1988) . Therefore, elevated endogenous dynorphin leads to motor dysfunctions (Faden, 1990; Malan et al., 2000) . Our present studies showed that in contrast to the neurotoxic effect of high doses of DYN, the intrathecal administration of a high dose of U50,488H also attenuates allodynia and hyperalgesia. Moreover, repeated administrations of minocycline, which reduce endogenous dynorphin levels, enhance the analgesic effects of U50,488H, which further confirms that DYN exerts its toxic effects via mechanisms distinct from opioid receptor, possibly through the involvement of glia cells besides NMDA receptor. Interestingly, our studies demonstrated a complete blockade of flaccid paralysis after high-dose DYN administration in rats previously receiving minocycline. These observations suggest beneficial, neuroprotective effects of minocycline and also the importance of microglia in the toxic effects of DYN. Minocycline has another important effect beyond the influence on endogenous prodynorphin levels, as shown by Machado et al. (2006) , who provided evidence that minocycline inhibits MMP-9 activity, which is increased in ischemia. Minocycline in ischemic models inhibited inflammation, microglial activation, apoptosis and the degradation of extracellular matrices, i.e., it exerted neuroprotective effects (Tikka and Koistinaho, 2001; Domercq and Matute, 2004) . In 2001 Tikka and Koistinaho have shown that minocycline prevented the NMDAinduced activation and proliferation of microglia and diminished the release of IL-1b in pure microglia cultures (Tikka and Koistinaho, 2001) . In 2007, we showed that minocycline exerted a neuroprotective function, and it even accelerated nerve regeneration . The data presented by Kawasaki et al. (2008) suggest that MMP-9 inhibition is beneficial for antagonizing neuropathic pain. Considering the role of MMP-9 and its endogenous inhibitor TIMP-1 in the development of neuropathy, this strong inhibitory effect of minocycline on MMP-9 mRNA expression might be the cause of the analgesic and neuroprotective effects. The intrathecal administration of the MMP-9 inhibitor attenuated mechanical allodynia and thermal hyperalgesia in our study, similar to minocycline administration. Our hypothesis was confirmed by our behavioral studies, which showed that intrathecal MMP-9 inhibitor administration prevented DYN-induced flaccid paralysis in a manner similar to minocycline.
The effects of minocycline on prodynorphin levels suggest an important role of microglia in the neurotoxicity of this peptide. Numerous literature data also suggest increased spinal IL-1b mRNA levels following injury (Wang et al., 2005; Lyons et al., 2007; Mika et al., 2008) . Other authors have suggested that the analgesic effects of minocycline during neuropathy are due to reduced IL-1b mRNA and TNF-a expression in the spinal cord (Ledeboer et al., 2005; Piao et al., 2006) . Both pro-and anti-inflammatory cytokines play important roles in nociceptive transmission and the regulation of neuropathic pain, and therefore, we studied the most important antinociceptive interleukins during neuropathic pain. Our experiments also demonstrated a strong increase in IL-1a and IL-10 mRNA levels in the DRG following CCI, which is consistent with our previous findings (Mika et al., 2008) , however minocycline administration as well as dynorphin administration does not affect this changes. Our results are consistent with those of Ledeboer et al. (2005) , who suggested that the analgesic effect of minocycline was not due to an increased expression of anti-inflammatory but to reduced levels of pro-inflammatory cytokines. The administration of high doses of DYN in a neuropathic pain model does not increase the already high level of the C1q-positive cells in the spinal cord and DRG, but it strongly increases the expression of proinflammatory cytokines IL-1b and IL-6 mRNA. Our data suggest that DYN does not induce microglia activation, but it can polarize microglia to an M1 type. Notably, our studies showed that intrathecal minocycline administration prevented DYN-induced flaccid paralysis and reduced the upregulation in IL-1b and IL-6 mRNA levels in the spinal cord and DRG, which suggests that these cytokines are responsible for the non-opioid adverse effects of dynorphin.
In conclusion, our studies revealed a very significant influence of repeated intrathecal minocycline administration on the prodynorphin system in the pathomechanism of neuropathic pain. Minocycline inhibited the development of flaccid paralysis following Fig. 1 . The effect of repeated intrathecal minocycline administration (MC, 60 mg/5 ml, 16 and 1 h before sciatic nerve injury and then once daily for 7 days), a single dose of dynorphin A (1e17) (DYN, 0.15 nmol and 15 nmol) and a combination of MC and DYN (MC þ DYN), a single dose of U50,488H (U50,488H, 25 nmol and 100 nmol) and MC and U50,488H on allodynia (A, C, E, G; von Frey test) and hyperalgesia (B, D, F, H; cold plate test), a single dose of norBNI (norBNI, 6.8 nmol and 13.6 nmol) and a combination of MC and norBNI (MC þ norBNI) on day 7 following sciatic nerve ligation (CCI). The results are presented as means ± SEM; the horizontal dotted line shows the naive group. The N group consisted of control naïve animals without sciatic nerve injury; the V þ V group consisted of animals with sciatic nerve ligation receiving vehicle (V); the MC þ V group consisted of animals with sciatic nerve ligation receiving MC; the V þ DYN/U50,488H/norBNI group consisted of animals with sciatic nerve ligation receiving repeated doses of V and a single dose of DYN/ U50,488H/norBNI; the MC þ DYN/U50,488H/norBNI group consisted of animals with sciatic nerve ligation receiving repeated doses of MC and a single dose of DYN/U50,488H/ norBNI. Inter-group differences were analyzed by ANOVA Bonferroni's Multiple Comparison Test: ***p < 0.001 indicates a significant difference marked only between control (naïve rats) and vehicle-treated CCI-exposed rats; # p < 0.05,
05, &&& p < 0.001 differences between MC þ V and MC þ U50,488H CCIexposed rats;^p < 0.05,^^^p < 0.001 differences between V þ DYN/norBNI and MC þ DYN/norBNI CCI-exposed rats. Vehicle (V; water for injection).
Table 2
The influence of norBNI (13.6 nmol, a highly selective kappa-opioid antagonist) on the dynorphin (DYN) analgesic (0.15 nmol) or neurotoxic (15 nmol) effects on day 7 following sciatic nerve ligation (CCI). The results are presented as means ± SEM. The N group consisted of control naïve animals without sciatic nerve injury; the V þ V group consisted of animals with sciatic nerve ligation receiving vehicle (V); the V þ DYN group consisted of animals with sciatic nerve ligation receiving a single dose of DYN; the norBNI þ DYN group consisted of animals with sciatic nerve ligation receiving a single doses of norBNI and a single dose of DYN. Inter-group differences were analyzed by ANOVA Bonferroni's Multiple Comparison Test: ***p < 0.001 indicates a significant difference marked only between control (naïve rats) and vehicle-treated CCI-exposed rats; # p < 0.05; ### p < 0.001 vs. V þ V CCI-exposed;^p < 0.05V þ DYN vs. norBNI þ DYN CCI-exposed; Vehicle (V; water for injection).
high-dose (15 nmol) DYN administration in rats. Our study showed that minocycline reduced prodynorphin and MMP-9 mRNA levels, which were previously elevated following sciatic nerve injury in the spinal cord and/or DRG. Additionally, minocycline prevented the upregulation of IL-1b and IL-6 mRNA following intrathecal DYN administration (15 nmol). This beneficial effect of minocycline can be related to a significant downregulation of MMP-9 mRNA, which was also supported by our pharmacological results. We have proven that a selective inhibitor of MMP-9 prevented flaccid paralysis induced by DYN, similarly to minocycline. The results of the Fig. 2 . The effect of repeated intrathecal minocycline administration (MC, 60 mg/5 ml, 16 and 1 h before sciatic nerve injury and then once daily for 7 days) on mRNA expression of anti-inflammatory interleukins IL-1a and IL-10 and pro-inflammatory cytokines IL-1b and IL-6 on day 7 following sciatic nerve ligation (CCI) as measured in the spinal cord (A, C, E, G) and DRG (B, D, F, H) . The values were standardized against HPRT. The results are presented as fold changes of control (N); the horizontal dotted line shows the naive group. The N group consisted of control naïve animals without sciatic nerve injury; the V þ V group consisted of animals with CCI receiving V; the MC þ V group consisted of animals with CCI receiving MC; the V þ DYN group consisted of animals with CCI receiving a single dose of dynorphin A (1e17) (DYN); the MC þ DYN group consisted of animals with CCI receiving repeated doses of MC and a single dose of DYN. Inter-group differences were analyzed by ANOVA Bonferroni's Multiple Comparison Test: *p < 0.05, ***p < 0.001 indicates a significant difference marked only between control (naïve rats) and vehicle-treated CCI-exposed rats; # p < 0.05, ### p < 0.001 vs. V þ V CCI-exposed; &&& p < 0.001 differences between MC þ V and MC þ DYN CCI-exposed rats;^p < 0.05,^^^p < 0.001 differences between V þ DYN and MC þ DYN CCI-exposed rats. Vehicle (V; water for injection).
present study shed new light on the mechanisms of action of dynorphin and suggest possible ways to modulate its adverse actions.
